Press Releases

• Active Biotech provides status update of its development programs
  Jul 8, 2025 08:30 (CEST)
• Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website
  Jun 30, 2025 17:15 (CEST)
• Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website
  Jun 9, 2025 16:50 (CEST)
• Annual General Meeting of Active Biotech AB
  May 28, 2025 18:30 (CEST) Regulatory
• Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma
  May 23, 2025 08:30 (CEST)